NASDAQ:PRAHPRA Health Sciences Stock Price, Forecast & News

PRA Health Sciences' stock was trading at $88.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PRAH shares have increased by 5.4% and is now trading at $93.45. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for PRA Health Sciences.

PRA Health Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for PRA Health Sciences.

PRA Health Sciences will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

PRA Health Sciences Inc (NASDAQ:PRAH) issued its earnings results on Thursday, April, 30th. The medical research company reported $1.05 earnings per share for the quarter, beating analysts' consensus estimates of $1.01 by $0.04. The medical research company earned $783.71 million during the quarter, compared to analyst estimates of $749.61 million. PRA Health Sciences had a return on equity of 27.59% and a net margin of 7.66%. The company's revenue was up 8.5% on a year-over-year basis. During the same quarter last year, the company earned $1.10 earnings per share. View PRA Health Sciences' earnings history.

PRA Health Sciences issued an update on its second quarter earnings guidance on Thursday, April, 30th. The company provided earnings per share guidance of $0.75-0.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.91. The company issued revenue guidance of $705-740 million, compared to the consensus revenue estimate of $666.91 million.

11 Wall Street analysts have issued twelve-month price objectives for PRA Health Sciences' stock. Their forecasts range from $82.00 to $120.00. On average, they expect PRA Health Sciences' stock price to reach $101.00 in the next year. This suggests a possible upside of 8.1% from the stock's current price. View analysts' price targets for PRA Health Sciences.

Media headlines about PRAH stock have trended negative this week, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PRA Health Sciences earned a coverage optimism score of -2.4 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news about PRA Health Sciences.

PRA Health Sciences saw a drop in short interest in June. As of June 30th, there was short interest totaling 1,580,000 shares, a drop of 10.7% from the June 15th total of 1,770,000 shares. Based on an average daily trading volume, of 454,000 shares, the days-to-cover ratio is presently 3.5 days. Approximately 2.5% of the shares of the stock are short sold. View PRA Health Sciences' Current Options Chain.

Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA) and Pieris Pharmaceuticals (PIRS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include Alibaba Group (BABA), NVIDIA (NVDA), Adobe (ADBE), Applied Materials (AMAT), Veeva Systems (VEEV), Walt Disney (DIS), Paypal (PYPL), Home Depot (HD), Lam Research (LRCX) and UnitedHealth Group (UNH).

(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Carnegie Capital Asset Management LLC (0.13%) and Envestnet Asset Management Inc. (0.02%). Company insiders that own PRA Health Sciences stock include Fund Holdings LP Kkr, Michael J Bonello and Pra Investors LP Kkr. View institutional ownership trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Carnegie Capital Asset Management LLC, and Envestnet Asset Management Inc.. Company insiders that have sold PRA Health Sciences company stock in the last year include Fund Holdings LP Kkr, and Michael J Bonello. View insider buying and selling activity for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $93.45.

PRA Health Sciences has a market capitalization of $5.95 billion and generates $3.07 billion in revenue each year. The medical research company earns $243.02 million in net income (profit) each year or $4.80 on an earnings per share basis. PRA Health Sciences employs 17,500 workers across the globe.

The official website for PRA Health Sciences is www.prahs.com.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]